Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet

Journal of Clinical Virology

Volumn 37, Issue 2, 2006, Pages 124-127

  Drew, W Lawrence ^a   Miner, Richard C ^a   Marousek, Gail I ^b,c   Chou, Sunwen ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cidofovir; Cytomegalovirus; Drug resistance; Foscarnet; Ganciclovir; Maribavir

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; GANCICLOVIR;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG SENSITIVITY; GENE MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS RESISTANCE; VIRUS STRAIN;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CYTOMEGALOVIRUS; CYTOSINE; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FOSCARNET; GANCICLOVIR; HUMANS; MUTATION; PHOSPHONIC ACIDS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RIBONUCLEOSIDES; VIRAL PROTEINS;

EID: 33748967780     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.07.010     Document Type: Article

References (16)

1. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith III A.A., Davis M.G., et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob Agents Chemother 46 (2002) 2365-2372
2. Chou S., Marousek G., Parenti D.M., Gordon S.M., LaVoy A.G., Ross J.G., et al. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J Infect Dis 178 (1998) 526-530
3. Chou S., Miner R.C., and Drew W.L. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J Infect Dis 182 (2000) 1765-1768
4. Chou S., Waldemer R.H., Senters A.E., Michels K.S., Kemble G.W., Miner R.C., et al. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 185 (2002) 162-169
5. Chou S., Lurain N.S., Thompson K.D., Miner R.C., and Drew W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 188 (2003) 32-39
6. Chou S., Marousek G.I., Senters A.E., Davis M.G., and Biron K.K. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 78 (2004) 7124-7130
7. Chou S., Van Wechel L.C., Lichy H.M., and Marousek G.I. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 49 (2005) 2710-2715
8. Chou S., Van Wechel L.C., and Marousek G.I. Effect of cell culture conditions on the anti-cytomegalovirus activity of maribavir. Antimicrob Agents Chemother 50 (2006) 2557-2559
9. Drew W.L., Miner R., and Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1 (1993) 179-185
10. Komazin G., Ptak R.G., Emmer B.T., Townsend L.B., and Drach J.C. Resistance of human cytomegalovirus to the benzimidazole l-ribonucleoside maribavir maps to UL27. J Virol 77 (2003) 11499-11506
11. Krosky P.M., Baek M.C., and Coen D.M. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol 77 (2003) 905-914
12. Krosky P.M., Baek M.C., Jahng W.J., Barrera I., Harvey R.J., Biron K.K., et al. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol 77 (2003) 7720-7727
13. McSharry J.J., McDonough A., Olson B., Talarico C., Davis M., and Biron K.K. Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole l-riboside 1263W94. Clin Diagn Lab Immunol 8 (2001) 1279-1281
14. Prichard M.N., Gao N., Jairath S., Mulamba G., Krosky P., Coen D.M., et al. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 73 (1999) 5663-5670
15. Williams S.L., Hartline C.B., Kushner N.L., Harden E.A., Bidanset D.J., Drach J.C., et al. In vitro activities of benzimidazole d- and l-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 47 (2003) 2186-2192
16. Wolf D.G., Courcelle C.T., Prichard M.N., and Mocarski E.S. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc Natl Acad Sci USA 98 (2001) 1895-1900